# EDGAR Filing Document

**Accession Number:** 0001829802
**File Stem:** 0001193125-26-279412
**Filing Date:** 2026-6
**Character Count:** 9414
**Document Hash:** 2b31df81fd5f14922747315cdc82ca44
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-279412.hdr.sgml**: 20260623

**ACCESSION NUMBER**: 0001193125-26-279412

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260623

**DATE AS OF CHANGE**: 20260623

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Faeth Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001829802
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92222
- **FILM NUMBER:** 261110968

**BUSINESS ADDRESS:**
- **STREET 1:** 701 TILLERY STREET #12 #1010
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78702
- **BUSINESS PHONE:** 512-200-2982

**MAIL ADDRESS:**
- **STREET 1:** 1405 RESEARCH BLVD, SUITE 125
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sensei Biotherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20201023
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** S2G Investments, LLC
- **CENTRAL INDEX KEY:** 0002022077

**ORGANIZATION NAME:**
- **EIN:** 933082776
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 210 N. CARPENTER STREET, SUITE 800
- **CITY:** CHICAGO
- **STATE:** IL
- **BUSINESS PHONE:** 312-873-8500

**MAIL ADDRESS:**
- **STREET 1:** 210 N. CARPENTER STREET, SUITE 800
- **CITY:** CHICAGO
- **STATE:** IL

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** S2G Investments. LLC
- **DATE OF NAME CHANGE:** 20240502

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** Faeth Therapeutics, Inc.

**Title of Class of Securities:** Common Stock, $0.0001 par value per share

**CUSIP Number:** —

**Date of Event Which Requires Filing of this Statement:** 06/15/2026

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>S2G Investments, LLC | Names of Reporting Persons<br>S2G Investments, LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>2575401 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>2575401 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2575401 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2575401 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.99% | Percent of Class Represented by Amount in Row (9)<br>9.99% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** In addition to the shares reported that were issued on June 15, 2026 upon conversion of shares of the Issuer's Series B Non-Voting Convertible Preferred Stock (the "Series B Preferred"), each of which was convertible into 1,000 shares of Common Stock, pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock filed by the Issuer with the Secretary of State of the State of Delaware on February 17, 2026 (the "Certificate of Designation"), the Reporting Person holds an additional 344.271 shares of Series B Preferred. The Series B Preferred is subject to a Beneficial Ownership Limitation set forth in Section 6.4 of the Certificate of Designation, which provides that the Reporting Person shall not have the right to acquire, and shall not be deemed to beneficially own for purposes of Section 13(d) of the Exchange Act, shares of Common Stock in excess of the percentage elected by the Reporting Person. The Reporting Person has elected a Beneficial Ownership Limitation of 9.99%. The percentage shown in Box 11 is based on 25,778,754 shares of Common Stock outstanding as of June 15, 2026, as confirmed by the Issuer. The shares of Common Stock underlying the Reporting Person's remaining 344.271 shares of Series B Preferred (representing approximately 344,271 additional shares of Common Stock on an as-converted basis) are not deemed beneficially owned by the Reporting Person pursuant to Section 6.4 of the Certificate of Designation. The reporting person, S2G Investments, LLC, serves as the investment manager to S2G Builders Food & Agriculture Fund III, LP. S2G Investments, LLC may be deemed to have beneficial ownership of the securities held directly by such entity. The entity and the reporting person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.

---

**Item 1(a). Name of Issuer:**
Faeth Therapeutics, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
1405 Research Blvd, Suite 125, Rockville, MD 20850

**Item 2(a). Name of Person Filing:**
S2G Investments, LLC

**Item 2(b). Address of Principal Business Office:**
210 N. Carpenter St., Floor 8, Chicago, IL 60607

**Item 2(c). Citizenship:**
Delaware

**Item 2(d). Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**Item 2(e). CUSIP Number:**
—

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [x] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

2,575,401

**(b) Percent of class:**

9.99%

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

2,575,401

**(ii) Shared power to vote or to direct the vote:**

0

**(iii) Sole power to dispose or to direct the disposition of:**

2,575,401

**(iv) Shared power to dispose or to direct the disposition of:**

0

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**S2G Investments, LLC**

**Date:** 06/23/2026

**By:** /s/ Sanjeev Krishnan

**Name & Title:** Sanjeev Krishnan, Managing Partner